Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 12, Issue 2, 2010, Pages 133-138

  Mudaliar, S ^a   Chang, A R ^b   Aroda, V R ^b   Chao, E ^b   Burke, P ^a   Baxi, S ^b   Griver, K A ^a   O'Connor, D T ^b   Henry, R R ^b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Body water composition; Insulin; Oedema; Pioglitazone; Renal salt handling; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; PLACEBO;

ADULT; ARTICLE; BODY FLUID COMPARTMENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; EXTRACELLULAR FLUID; EXTRAVASCULAR FLUID; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; INTRACELLULAR FLUID; KIDNEY TUBULE ABSORPTION; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PLASMA VOLUME; RANDOMIZED CONTROLLED TRIAL; SODIUM BALANCE; TOTAL BODY WATER; WEIGHT GAIN;

EID: 73349107151     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01126.x     Document Type: Article

References (29)

1. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004, 351:1106-1118.
2. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999, 22:288-293.
3. Miyazaki Y, Mahankali A, Matsuda M. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002, 87:2784-2791.
4. Staels B. Fluid retention mediated by renal PPARgamma. Cell Metab 2005, 2:77-78.
5. Skott P, Vaag A, Bruun NE. Effect of insulin on renal sodium handling in hyperinsulinaemic type 2 (non-insulin-dependent) diabetic patients with peripheral insulin resistance. Diabetologia 1991, 34:275-281.
6. Sotiropoulos KB, Clermont A, Yasuda Y. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. FASEB J 2006, 20:1203-1205.
7. ter Maaten JC, Bakker SJ, Serne EH, ter Wee PM, Donker AJ, Gans RO. Insulin's acute effects on glomerular filtration rate correlate with insulin sensitivity whereas insulin's acute effects on proximal tubular sodium reabsorption corelation with salt sensitivity in normal subjects. Nephrol Dial Transplant 1999, 14:2357-2363.
8. Emoto M, Anno T, Sato Y. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes 2001, 50:1166-1170.
9. Guan Y, Hao C, Cha DR. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005, 11:861-866.
10. Mamoulakis D, Bitsori M, Galanakis E, Raissaki M, Kalmanti M. Insulin-induced oedema in children and adolescents. J Paediatr Child Health 2006, 42:655-657.
11. 2000, Avandia (Prescribing information). Philadelphia, Smith Kline Beecham Pharmaceuticals, April
12. Actos (Prescribing information). Lincolnshire, Takeda; Indianapolis, Elli Lilly Company, July 2002.
13. Brijker F, Heijdra YF, Van Den Elshout FJ, Bosch FH, Folgering HT. Volumetric measurements of peripheral oedema in clinical conditions. Clin Physiol 2000, 20:56-61.
14. Moissl UM, Wabel P, Chamney PW. Body fluid volume determination via body composition spectroscopy in health and disease. Physiol Meas 2006, 27:921-933.
15. Thomas BJ, Ward LC, Cornish BH. Bioimpedance spectrometry in the determination of body water compartments: accuracy and clinical significance. Appl Radiat Isot 1998, 49:447-455.
16. Androne AS, Katz SD, Lund L. Hemodilution is common in patients with advanced heart failure. Circulation 2003, 107:226-229.
17. Recommended methods for measurement of red-cell and plasma volume. J Nucl Med 1980, 21:793-800. International Committee for Standardization in Haematology
18. Perrone RD, Steinman TI, Beck GJ. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and insulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis 1990, 16((3)):224-235.
19. Weinberger MH, Smith JB, Fineberg NS, Luft FC. Red-cell sodium-lithium countertransport and fractional excretion of lithium in normal and hypertensive humans. Hypertension 1989, 13:206-212.
20. Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006, 29:510-514.
21. Berria R, Glass L, Mahankali A. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther. 2007, 82:275-281.
22. Hsueh WA, Nicholas SB. Peroxisome proliferator-activated receptor-gamma in the renal mesangium. Curr Opin Nephrol Hypertens 2002, 11:191-195.
23. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A 2005, 102:9406-9411.
24. Kirchner KA. Lithium as a marker for proximal tubular delivery during low salt intake and diuretic infusion. Am J Physiol 1987, 253:F188-F196.
25. Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner HR, Burnier M. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004, 89:1140-1145.
26. Rennings AJ, Smits P, Stewart MW, Tack CJ. Fluid retention and vascular effects rosiglitazone in obese, insulin-resistant, nondiabetic subjects. Diabetes Care 2006, 29:581-587.
27. Tooke JE, Elston LM, Gooding KM. The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin. Diabetologia 2006, 49:1064-1070.
28. Baba T, Shimada K, Neugebauer S, Yamada D, Hashimoto S, Watanabe T. The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. Diabetes Care 2001, 24:953-954.
29. Barbier O, Torra IP, Duguay Y. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002, 22:717-726.